Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Esperion's Japan Partner Otsuka Pharmaceutical Gets National Health Insurance Price Listing To Roll Out NEXLETOL For Hypercholesterolemia, Familial Hypercholesterolemia Treatment

Author: Benzinga Newsdesk | November 21, 2025 08:01am

Esperion (NASDAQ:ESPR) today announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka), the Company's partner in Japan for the development and commercialization of NEXLETOL® (bempedoic acid) tablets, received National Health Insurance Price Listing and launched NEXLETOL for the treatment of hypercholesterolemia and familial hypercholesterolemia.

Posted In: ESPR


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist